Buspirone (HCl)

Buspirone (HCl) is anxiolytic agent and a 5-HT 1 agonist. Buspirone (HCl) is a new non-benzodiazepine. It relieves nervousness, anxiety. Unlike benzodiazepines the drug has less side effects.

Buspirone (HCl) is primarily indicated in conditions like Generalized anxiety disorder, Non-specific anxiety symptoms, Suppression of transplant rejection, Smoking cessation(off label)

Buspirone (HCl) is contraindicated in conditions like Epilepsy,Hypersensitivity,Renal impairment,Hepatic impairment.

The signs and symptoms that are produced after the acute over dosage of Buspirone (HCl) include Nausea, Vomiting, Drowsiness, Gastric distress, Dizziness, Miosis.The symptomatic adverse reactions produced by Buspirone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Vomiting, Gastric complaints, Sleeplessness, Uneasiness, Blurred vision, Confusion, Excitement, Insomnia, Myalgia, numbness, Rashes

Buspirone should be used with caution in patients with kidney or liver impairment. Patient should observe caution while driving or performing other task requiring alertness. May cause cognitive motor impairment, Restlessness syndrome associated with therapy.

Drug should not be given to Pediatrics, Pregnant Mothers, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

5 mg (5 (5)) 12 hourly PO — Increased by 5 mg every 2-3 days.

( ) — Not recommended in this age group

( ) — Not recommended in this age group

Buspirone (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAmisulprideIncreased sedative effects when antipsychotics (e.g Amisulpride) given with hypnotics (e.g Buspirone)DigoxinIncreases plasma concentration of Digoxin.Diltiazem (HCl)Erythromycinplasma concentration of Buspirone increased by Erythromycin.MajorReduce dose of Buspirone.HaloperidolBuspirone increases plasma concentration of Haloperidol.Iproniazid PhosphateTheoretical potential for BUSPIRONE HYDROCHLORIDE increasing the HYPERTENSIVE effect of IPRONIAZID. Potential risk. AvoidItraconazoleMethotrimeprazine (Maleate)ParoxetinePromazine (HCl)SulpirideTrazodone (HCl)Verapamil (HCl)VORICONAZOLEVoriconazole may increase the serum concentration of buprenorphine by decreasing its metabolismMonitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store in a well closed container, Below 40°C. Protect from Sunlight and Moisture.